| Bioactivity | Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist[1]. Sipagladenant can be used in frontal lobe dysfunction research[2]. |
| In Vivo | Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex[2].Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior[2].Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters[2]. Animal Model: |
| Name | Sipagladenant |
| CAS | 858979-50-7 |
| Formula | C20H19N3O4S |
| Molar Mass | 397.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true [2]. Horita, Takako. THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION, WO2016148308A1. |
Sipagladenant
CAS: 858979-50-7 F: C20H19N3O4S W: 397.45
Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist. Sipagladenant can be used in fron
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.